Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing
-
Letto da:
-
Di:
In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories:
- Early Notes from The Psychedelic Healthcare Forum
- FDA Floats an Ibogaine Trial Design, Asks Field for Input
- Compass Talks Pricing, Label and a Slow Launch
- New Mexico Nears Medical Psilocybin Launch
- Six More Potential Psychedelic Brand Names
Read more:
- Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
- The Psychedelic Practitioner Issue 7: Preparedness (Systems)
The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.
This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.
Send us your questions and comments at pod@psychedelicalpha.com
Read more and join our newsletter at https://psychedelicalpha.com
Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.
Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/